AbbVie Inc., a global biopharmaceutical leader headquartered in the United States, was established in 2013 as a spin-off from Abbott Laboratories. With a strong presence in North America, Europe, and Asia, AbbVie focuses on developing advanced therapies in immunology, oncology, neuroscience, and virology. The company is renowned for its flagship product, Humira, which has transformed the treatment landscape for autoimmune diseases. AbbVie’s commitment to innovation is evident in its robust pipeline of biologics and small molecules, addressing unmet medical needs. Recognised for its significant contributions to healthcare, AbbVie consistently ranks among the top biopharmaceutical companies worldwide, driven by a mission to improve patient outcomes through science and research.
How does Abbvie's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Abbvie's score of 48 is higher than 87% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, AbbVie reported total carbon emissions of approximately 300,072,000 kg CO2e for Scope 1 and 122,287,000 kg CO2e for Scope 2, resulting in a combined total of about 422,359,000 kg CO2e. This marks a decrease from 2023, where emissions were approximately 328,259,000 kg CO2e for Scope 1 and 131,232,000 kg CO2e for Scope 2, totalling around 459,491,000 kg CO2e. In 2022, AbbVie’s emissions were approximately 342,607,000 kg CO2e for Scope 1 and 184,549,000 kg CO2e for Scope 2, with an additional 527,156,000 kg CO2e reported for Scope 3 emissions. AbbVie has set ambitious climate commitments, aiming to reduce absolute Scope 1 and 2 greenhouse gas emissions by 42% by 2030, using 2021 as the base year. This target includes increasing the sourcing of renewable electricity from 29.5% in 2021 to 100% by 2030. Furthermore, AbbVie plans for 79.1% of its suppliers, covering purchased goods and services, capital goods, and upstream transportation and distribution, to have science-based targets by 2027. These initiatives align with industry standards for climate action and demonstrate AbbVie’s commitment to sustainability and reducing its carbon footprint.
Access structured emissions data, company-specific emission factors, and source documents
2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|---|---|---|---|---|
Scope 1 | 402,448,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Scope 2 | 418,473,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Scope 3 | - | - | - | - | - | - | - | 000,000,000 | - | - |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Abbvie is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.